Modeling cyclooxygenase inhibition. Implication of active site hydration on the selectivity of ketoprofen analogues

Journal of Medicinal Chemistry

Volumn 43, Issue 11, 2000, Pages 2280-2284

  Palomer, Albert ^a   Pérez, Juan J ^b   Navea, Susana ^a   Llorens, Oriol ^b   Pascual, Jaume ^a   García, Lluïsa ^a   Mauleón, David ^a  

^a Laboratorios Menarini   (Spain)

^b UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

KETOPROFEN; PROSTAGLANDIN SYNTHASE;

ARTICLE; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYDRATION; HYDROGEN BOND; MOLECULAR MODEL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING SITES; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; KETOPROFEN; MODELS, MOLECULAR; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; WATER;

EID: 0342803187     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9906217     Document Type: Article

References (32)

1. Flower, R. J.; Vane, J. R. Inhibition of Prostaglandin Synthetase in Brain explains the Anti-pyretic Activity of Paracetamol (4-acetamidophenol). Nature 1972, 240, 410-411.
2. Xie, W.; Chipmann, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a Mitogen-Responsive Gene Encoding Prostaglandin Synthase is Regulated by mRNA Splicing. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2692.
3. Smith, W. L.; Garavito, R. M.; DeWitt, D. L. Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and -2. J. Biol. Chem. 1996, 277, 33157-33160.
4. Enrich, E.; Dallob, A.; van Hecken, A.; Depre, M.; DeLepeleire, I.; Brideau, C.; Hilliard, D.; Tanaka, W.; Mukhopadhyay, S.; Seibold, J.; DeSchepper, P.; Gertz, B. Demonstration of Selective COX-2 Inhibition by MK-966 in Humans. Arthr., Rheumatism 1996, 39 (9) s81 (Abstr. 328).
5. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene sulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 0 (9) 1347-1365.
6. Hawkey, C. J. COX-2 Inhibitors. Lancet 1999, 353, 307-314.
7. Picot, D.; Loll, P. J.; Garavito, R. M. The X-ray Crystal Structure of the Membrane Protein Prostaglandin H2 Synthase-1. Nature 1994, 367, 243-249.
8. McKeever, B. M.; Pandya, S.; Percival, M. D.; Ouellet, M.; Bayly, C.; O'Neill, G. P.; Bastien, L.; Kennedy, B. P.; Adam, M.; Cromlish, W.; Roy, P.; Black, W. C.; Guay, D.; LeBlanc, Y. Crystal Structure of Recombinant Human COX-2 at 3.0 Å Resolution. 10th Conf. Prost., Related Compds. 1996, 55 (1), 20 (Abstr. 63).
9. Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M. F. Flexibility of the NSAID Binding Site in the Structure of Human Cyclooxygenase-2. Nature Struct. Biol. 1996, 3, 927-933.
10. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural Basis for the Selective Inhibition of Cyclooxygenase-2 by Antiinflammatory Agents. Nature 1996, 384, 644-648.
11. Filizola, M.; Pérez, J. J.; Palomer, A.; Mauleón, D. Comparative Molecular Modeling Study of the Three-Dimensional Structures of Prostaglandin Endoperoxide H2 Synthase 1 and 2 (COX-1 and COX-2). J. Mol Graph. 1997, 15, 290-300.
12. Garavito, R. M. The Cyclooxygenase-2 Structure: New Drugs for an Old Target? Nature Struct. Biol. 1996, 3 (11), 897-901.
13. Copeland, R. A.; Williams, J. M.; Giannaras, J.; Nurnberg, Sh.; Covington, M.; Pinto, D.; Pick, S.; Trzakos, J. M. Mechanism of Selective Inhibition of the Inducible Isoform of Prostaglandin G/H Synthase. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 11202-11206.
14. So, O. Y.; Scarafia, L. E.; Mak, A. Y.; Callan, O. H.; Swinney, D. C. Dynamics of Prostaglandin H Synthases-Studies with Prostaglandin H Synthase 2 Y355F Unmask Mechanisms of Time-Dependent Inhibition and Allosteric Activation. J. Biol. Chem. 1998, 273 (10), 5801-5807.
15. Kothekar, V.; Sahi, S.; Srinivasan, M. Computer Simulation of the Interaction of Non-Steroidal Antiinflammatory Drugs: Indoprofen and NS398 with Cyclooxygenase. J. Biomol. Struct., Dyn. 1999, 16 (4), 901-915.
16. Bayly, C. I.; Black, C.; Leger, S.; Ouimet, N.; Ouellet, M.; Percival, M. D. Structure-based Design of COX-2 Selectivity into Flurbiprofen. Bioorg. Med. Chem. Lett. 1999, 9, 307-312.
17. Meiering, E. M.; Wagner, G. Detection of Long-Lived Water Molecules in Complexes of Dihydrofolate Reductase with Methorexate and NADPH. J. Mol. Biol. 1995, 247, 294-308.
18. Pastor, M.; Cruciani, G.; Watson K. A. A Strategy for the Incorporation of Water Molecules Present in a Ligand Binding Site into a Three-Dimensional Structure-Activity Relationship Analysis. J. Med. Chem. 1997, 40, 4089-4102 and references therein.
19. Poornima, C. S.; Dean, P. M. Hydration in Drug Design. 1 Multiple Hydrogen-Bonding Features of Water Molecules in Mediating Water-Ligand Interactions. J. Comput.-Aided Mol. Des. 1995, 9, 500-512. Poornima, C. S.; Dean, P. M. Hydration in Drug Design. 2. Influence of Local Site Surface Shape on Water Binding. J. Comput.-Aided Mol. Des. 1995, 9, 513-520. Poornima, C. S.; Dean, P. M. Hydration in Drug Design. 3. Conserved Water Molecules at the Binding Site of Homologous Proteins. J. Comput.-Aided Mol. Des. 1995, 9, 521-531.
20. Poornima, C. S.; Dean, P. M. Hydration in Drug Design. 1 Multiple Hydrogen-Bonding Features of Water Molecules in Mediating Water-Ligand Interactions. J. Comput.-Aided Mol. Des. 1995, 9, 500-512. Poornima, C. S.; Dean, P. M. Hydration in Drug Design. 2. Influence of Local Site Surface Shape on Water Binding. J. Comput.-Aided Mol. Des. 1995, 9, 513-520. Poornima, C. S.; Dean, P. M. Hydration in Drug Design. 3. Conserved Water Molecules at the Binding Site of Homologous Proteins. J. Comput.-Aided Mol. Des. 1995, 9, 521-531.
21. Poornima, C. S.; Dean, P. M. Hydration in Drug Design. 1 Multiple Hydrogen-Bonding Features of Water Molecules in Mediating Water-Ligand Interactions. J. Comput.-Aided Mol. Des. 1995, 9, 500-512. Poornima, C. S.; Dean, P. M. Hydration in Drug Design. 2. Influence of Local Site Surface Shape on Water Binding. J. Comput.-Aided Mol. Des. 1995, 9, 513-520. Poornima, C. S.; Dean, P. M. Hydration in Drug Design. 3. Conserved Water Molecules at the Binding Site of Homologous Proteins. J. Comput.-Aided Mol. Des. 1995, 9, 521-531.
22. GRID version 17.0; Molecular Discovery Ltd., Oxford, 1998.
23. Goodford, P. J. A Computational Procedure for Determining Energetically Favourable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857. Boobbyer, D. N. A.; Goodford, P. J.; McWhinnie, P. M.; Wade, C. R. New Hydrogen Bond Potentials for use in Determining Energetically Favorable Binding Sites in Molecules of Known Structure. J. Med. Chem. 1989, 32, 1083-1094. Wade, C. R.; Clark, K. J.; Goodford, P. J. Further Development of Hydrogen Bond Functions for the Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. 2. Ligand Probe Groups with the Ability to Form Two Hydrogen Bonds J. Med. Chem. 1993, 36, 140-147. Wade, C. R.; Goodford, P. J. Further Development of Hydrogen Bond Functions for the Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. 2. Ligand Probe Groups with the Ability to Form More than Two Hydrogen Bonds J. Med. Chem. 1993, 36, 148-156.
24. Goodford, P. J. A Computational Procedure for Determining Energetically Favourable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857. Boobbyer, D. N. A.; Goodford, P. J.; McWhinnie, P. M.; Wade, C. R. New Hydrogen Bond Potentials for use in Determining Energetically Favorable Binding Sites in Molecules of Known Structure. J. Med. Chem. 1989, 32, 1083-1094. Wade, C. R.; Clark, K. J.; Goodford, P. J. Further Development of Hydrogen Bond Functions for the Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. 2. Ligand Probe Groups with the Ability to Form Two Hydrogen Bonds J. Med. Chem. 1993, 36, 140-147. Wade, C. R.; Goodford, P. J. Further Development of Hydrogen Bond Functions for the Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. 2. Ligand Probe Groups with the Ability to Form More than Two Hydrogen Bonds J. Med. Chem. 1993, 36, 148-156.
25. Goodford, P. J. A Computational Procedure for Determining Energetically Favourable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857. Boobbyer, D. N. A.; Goodford, P. J.; McWhinnie, P. M.; Wade, C. R. New Hydrogen Bond Potentials for use in Determining Energetically Favorable Binding Sites in Molecules of Known Structure. J. Med. Chem. 1989, 32, 1083-1094. Wade, C. R.; Clark, K. J.; Goodford, P. J. Further Development of Hydrogen Bond Functions for the Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. 2. Ligand Probe Groups with the Ability to Form Two Hydrogen Bonds J. Med. Chem. 1993, 36, 140-147. Wade, C. R.; Goodford, P. J. Further Development of Hydrogen Bond Functions for the Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. 2. Ligand Probe Groups with the Ability to Form More than Two Hydrogen Bonds J. Med. Chem. 1993, 36, 148-156.
26. Goodford, P. J. A Computational Procedure for Determining Energetically Favourable Binding Sites on Biologically Important Macromolecules. J. Med. Chem. 1985, 28, 849-857. Boobbyer, D. N. A.; Goodford, P. J.; McWhinnie, P. M.; Wade, C. R. New Hydrogen Bond Potentials for use in Determining Energetically Favorable Binding Sites in Molecules of Known Structure. J. Med. Chem. 1989, 32, 1083-1094. Wade, C. R.; Clark, K. J.; Goodford, P. J. Further Development of Hydrogen Bond Functions for the Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. 2. Ligand Probe Groups with the Ability to Form Two Hydrogen Bonds J. Med. Chem. 1993, 36, 140-147. Wade, C. R.; Goodford, P. J. Further Development of Hydrogen Bond Functions for the Use in Determining Energetically Favorable Binding Sites on Molecules of Known Structure. 2. Ligand Probe Groups with the Ability to Form More than Two Hydrogen Bonds J. Med. Chem. 1993, 36, 148-156.
27. Loll, P.; Picot, D.; Garavito, R. M. The Structural Basis of Aspirin Activity Inferred from the Crystal Structure of Inactivated Prostaglandin H-2 Synthase. Nature Str. Biol. 1995, 2 (8), 637-643.
28. A detailed method for the obtention of compounds 2-3 has been previously described in: Mauleón, D.; Pascual, J.; Garcia, M. L.; Palomer, A.; Lopez, F.; Marti, J.; Ballart, B.; a-arylpropionic and arylacetic acids as Ciclooxygenase-II inhibitors. Patent ES-9901628, 1999 (priority 13 Aug, 1999).
29. Entry 3PGH in the Protein Brookhaven Databank.
30. InsightII 97. Molecular Simulations Inc. San Diego CA, 1997.
31. Discover version 2.98; Molecular Simulations Inc., San Diego CA, 1997.
32. Carabaza, A.; Cabré, F.; Rotllan, E.; Gömez, M.; Gutiérrez, M.; García, M. L.; Mauleón, D. Stereoselective inhibition of inducible cyclooxygenase by chiral non steroidal antiinflamatory drugs. J. Clin. Pharmacol. 1996, 36, 505-512.